A degrader of HER2 and EGFR abolishes p95HER2 and shows robust antitumor efficacy in HER2-positive breast cancer

曲妥珠单抗 癌症研究 表皮生长因子受体 拉帕蒂尼 乳腺癌 细胞培养 癌症 医学 受体 人表皮生长因子受体2 表皮生长因子受体抑制剂 抗药性 帕妥珠单抗 生物 癌细胞 细胞外 生长因子受体 信号转导 细胞生长 表皮生长因子 药品 表型 转移性乳腺癌 重组DNA 人体乳房 化学 抗体 生长抑制 细胞 肿瘤
作者
Lu Yang,Arup Bhattacharya,Yun Li,Darrell Peterson,Yuesheng Zhang
出处
期刊:Scientific Reports [Nature Portfolio]
卷期号:16 (1)
标识
DOI:10.1038/s41598-026-47444-3
摘要

p95HER2 is commonly expressed in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) and is generated primarily from shedding of the extracellular domain of HER2. p95HER2 is oncogenic, driving aggressive tumor growth, and conferring drug resistance. Targeting p95HER2 is challenging. Clinically approved HER2 inhibitors either cannot bind to p95HER2 or show limited inhibitory effects. We used cell lines and orthotopic tumor models (cell line xenografts and patient derived xenografts) to investigate the effects of HER2 inhibitors on p95HER2 and other key signaling proteins in HER2-positive BC, and to compare the therapeutic activities of different HER2 inhibitors. The HER2 inhibitors represent different mechanisms of actions, including trastuzumab, pertuzumab, tucatinib, and lapatinib, all of which are clinically approved, as well as PEPD G278D , a recombinant human protein which was previously shown to induce the degradation of HER2 and epidermal growth factor receptor (EGFR). EGFR is closely related to HER2 and is implicated in drug resistance in HER2-positive BC. HER2-positive BC cells and tumors, despite p95HER2 expression, are exquisitely sensitive to targeted degradation of HER2 and EGFR by PEPD G278D . PEPD G278D -induced degradation of HER2 also consistently eliminates p95HER2. PEPD G278D is far more effective than the clinically approved HER2 inhibitors in inhibiting the oncogenic signaling and growth of HER2-positive BC cells and tumors expressing p95HER2. Most notably, in an orthotopic PDX of HER2-positive BC expressing p95HER2, which is insensitive to trastuzumab and tucatinib, PEPD G278D achieved complete and lasting tumor elimination. Despite p95HER2 expression and resistance to current HER2 inhibitors, HER2-positive BC cells and tumors are highly vulnerable to PEPD G278D -induced degradation of HER2 and EGFR. By inducing HER2 degradation, PEPD G278D eliminates p95HER2 in HER2-positive BC cells and tumors.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wangjing11完成签到,获得积分10
刚刚
呜呼完成签到,获得积分10
1秒前
hashtag完成签到,获得积分10
1秒前
梵强斯完成签到,获得积分10
1秒前
1秒前
hsss完成签到,获得积分10
2秒前
芑璇完成签到,获得积分10
2秒前
一叶知秋完成签到,获得积分10
2秒前
晏旭完成签到,获得积分10
3秒前
睡觉觉了完成签到,获得积分10
3秒前
NorthWang完成签到,获得积分10
3秒前
是驼驼呀发布了新的文献求助10
3秒前
传统的雨文完成签到,获得积分10
4秒前
研友_Lw7MKL完成签到,获得积分10
4秒前
课题组刀刃完成签到,获得积分10
4秒前
xiaofan1991完成签到,获得积分10
5秒前
suiwuya完成签到,获得积分10
6秒前
xiaoxiao完成签到,获得积分10
6秒前
飞柱杀手桃白白完成签到,获得积分0
7秒前
忧心的曼凝的应助被木木采纳,获得10
7秒前
123完成签到 ,获得积分10
7秒前
解我鞋带干嘛完成签到,获得积分10
7秒前
是昭昭呀完成签到,获得积分10
8秒前
班小班完成签到,获得积分10
8秒前
9秒前
liujunhong完成签到,获得积分10
10秒前
changjiaren完成签到,获得积分10
10秒前
马晓玲完成签到,获得积分10
10秒前
Amy完成签到,获得积分10
11秒前
Dorren完成签到,获得积分10
11秒前
水易而华完成签到,获得积分10
11秒前
lilli完成签到,获得积分0
12秒前
523完成签到,获得积分10
12秒前
曾无忧完成签到,获得积分10
13秒前
勤劳凡雁完成签到,获得积分10
13秒前
Jyao完成签到,获得积分10
13秒前
害怕的小刺猬完成签到 ,获得积分10
13秒前
四叶草哦完成签到,获得积分10
13秒前
水煮电吹风的应助被情况有变采纳,获得10
14秒前
珍惜眼前人完成签到,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180146
求助须知:如何正确求助?哪些是违规求助? 9570319
关于积分的说明 21809739
捐赠科研通 7776294
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039